Brief: Aurobindo Pharma Says US FDA Inspects Unit-VII In Telangana
06/05/2026 04:44
May 6 (Reuters) - Aurobindo Pharma Ltd ARBN.NS: AUROBINDO PHARMA - US FDA INSPECTS AUROBINDO PHARMA UNIT-VII IN TELANGANA FROM JAN 28 TO FEB 10, 2026 AUROBINDO PHARMA - US FDA ISSUES FORM 483 WITH 9 OBSERVATIONS FOR AUROBINDO PHARMA UNIT-VII AUROBINDO PHARMA - UNIT RECEIVES EIR CLASSIFIED AS "VOLUNTARY ACTION INDICATED", FDA HAS CONCLUDED THAT THIS INSPECTION IS NOW CLOSED Source text: ID:nBSE15L6dt Further company coverage: ARBN.NS ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Aurobindo Pharma
See all newsBrief: Aurobindo Pharma Gets Tax Order Confirming Total Disputed Amount 46 Million Rupees
India's Aurobindo Pharma falls after US FDA flags observation at Telangana facility
Brief: Aurobindo Pharma Says US FDA Inspected API Manufacturing Facility Of Unit Apitoria Pharma
Brief: Aurobindo Pharma Gets USFDA Final Approval For Beclomethasone Dipropionate HFA Inhalation Aerosol
Brief: Aurobindo Pharma Says US FDA Inspected Unit-IV Of Apitoria Pharma From September 7 To September 11